Bio Financial Statements From 2010 to 2025

Stocks . Australia . 
Stock . Bio Gene Technology
BGT Stock   0.03  0  2.94%   
Bio Gene financial statements provide useful quarterly and yearly information to potential Bio Gene Technology investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Bio Gene financial statements helps investors assess Bio Gene's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Bio Gene's valuation are summarized below:
Gross Profit
-301.4 K
Market Capitalization
6.6 M
Enterprise Value Revenue
10.7329
Revenue
18.3 K
Earnings Share
(0.01)
There are currently seventy-eight fundamental signals for Bio Gene Technology that can be evaluated and compared over time across rivals. All traders should validate Bio Gene's prevailing fundamentals against the performance from 2010 to 2025 and make sure the trends continue to evolve in the right direction.

Bio Gene Total Revenue

20,014.6

Check Bio Gene financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bio Gene's main balance sheet or income statement drivers, such as Depreciation And Amortization of 39.4 K, Interest Expense of 63.8 K or Selling General Administrative of 1.7 M, as well as many indicators such as . Bio financial statements analysis is a perfect complement when working with Bio Gene Valuation or Volatility modules.
  
This module can also supplement various Bio Gene Technical models . Check out the analysis of Bio Gene Correlation against competitors.

Bio Gene Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets5 M3.6 M3.7 M
Slightly volatile
Other Current Liabilities384 K343.5 K264.3 K
Slightly volatile
Total Current Liabilities466.3 K397.8 K319.5 K
Slightly volatile
Total Stockholder Equity4.5 M3.2 M3.3 M
Slightly volatile
Property Plant And Equipment Net26 K21.9 K20.7 K
Slightly volatile
Cash4.1 M2.5 M3 M
Slightly volatile
Non Current Assets Total271.5 K200 K298.3 K
Pretty Stable
Cash And Short Term Investments4.1 M2.5 M3 M
Slightly volatile
Common Stock Shares Outstanding141.8 M213.7 M124.5 M
Slightly volatile
Liabilities And Stockholders Equity5 M3.6 M3.7 M
Slightly volatile
Other Current Assets167.8 K234.5 K139.4 K
Slightly volatile
Total Liabilities601.7 K423.7 K430.1 K
Slightly volatile
Total Current Assets4.6 M3.4 M3.4 M
Slightly volatile
Intangible Assets252.5 K182.9 K278.3 K
Very volatile
Common Stock13 M24.8 M10.7 M
Slightly volatile
Property Plant Equipment26.6 K16.8 K20.2 K
Slightly volatile
Net Receivables401.8 K602.6 K293.2 K
Slightly volatile
Other Liabilities21.8 K22.9 K196.5 K
Slightly volatile
Accounts Payable40.4 K42.5 K79 K
Slightly volatile
Non Current Liabilities Total19.3 K20.3 K196.9 K
Slightly volatile
Short and Long Term Debt Total168.2 K172.5 K153.3 K
Slightly volatile
Common Stock Total Equity13.8 M16.7 M13.2 M
Slightly volatile
Short Term Investments2.6 M1.4 M2.3 M
Very volatile
Net Invested Capital4.4 M2.5 M6.6 M
Slightly volatile
Property Plant And Equipment Gross47.9 K64.7 K40.1 K
Slightly volatile
Net Working Capital4.1 M2.3 M6.3 M
Slightly volatile
Capital Stock18.7 M24.8 M15 M
Slightly volatile
Cash And Equivalents3.7 M3.5 M4.3 M
Slightly volatile
Capital Lease Obligations9.3 K10.5 K11.4 K
Slightly volatile

Bio Gene Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization39.4 K44.1 K30 K
Slightly volatile
Selling General Administrative1.7 M1.6 M550.3 K
Slightly volatile
Total Revenue20 K21.1 K253.9 K
Slightly volatile
Other Operating Expenses2.5 M3.5 M2 M
Slightly volatile
Research Development1.2 M1.2 M931.7 K
Slightly volatile
Total Operating Expenses2.3 M3.2 M1.8 M
Slightly volatile
Interest Income60.7 K78.3 K98.8 K
Slightly volatile
Reconciled Depreciation37.4 K34.5 K43.3 K
Very volatile

Bio Gene Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation39.4 K44.1 K30 K
Slightly volatile
End Period Cash Flow3.3 M2.5 M2.5 M
Slightly volatile
Change To Netincome590.2 K562.1 K259 K
Slightly volatile
Begin Period Cash Flow3.7 M3.4 M2.5 M
Slightly volatile
Stock Based Compensation53.2 K56 K118.8 K
Slightly volatile
Issuance Of Capital Stock2.2 M2.3 M1 M
Slightly volatile
Dividends Paid90.6 K86.2 K34.4 K
Slightly volatile

Bio Fundamental Market Drivers

Cash And Short Term Investments2.2 M

About Bio Gene Financial Statements

Bio Gene shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Bio Gene investors may analyze each financial statement separately, they are all interrelated. The changes in Bio Gene's assets and liabilities, for example, are also reflected in the revenues and expenses on on Bio Gene's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Total Revenue21.1 K20 K
Cost Of Revenue367.7 K200.5 K

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.
Explore Investing Ideas  

Additional Tools for Bio Stock Analysis

When running Bio Gene's price analysis, check to measure Bio Gene's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio Gene is operating at the current time. Most of Bio Gene's value examination focuses on studying past and present price action to predict the probability of Bio Gene's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio Gene's price. Additionally, you may evaluate how the addition of Bio Gene to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2024 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY